Fibroscan Hepatic Fibrosis Screening to Power

Fibroscan Hepatic Fibrosis Screening to Power
1 / 1
Fibroscan Hepatic Fibrosis Screening to Power - slide 1 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 2 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 3 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 4 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 5 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 6 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 7 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 8 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 9 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 10 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 11 of 12 Fibroscan Hepatic Fibrosis Screening to Power - slide 12 of 12
Fibroscan Hepatic Fibrosis Screening to Power Patient Motivation, Quality and Prestige in Your Practice Fibroscan is Always Zero Out-of-Pocket Cost for Commercial Insurance 140 covered by Medicare The American Diabetes Association says

Related Topics

Download this presentation From Below

"Fibroscan Hepatic Fibrosis Screening to Power" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

01
Fibroscan Hepatic Fibrosis Screening to Power Patient Motivation, Quality and Prestige in Your Practice Fibroscan is Always Zero Out-of-Pocket Cost for Commercial Insurance $140 covered by Medicare<br>
02
The American Diabetes Association says that the time is now to screen for metabolic dysfunction-associated statohepatitis (MASH)-related liver fibrosis<br>
03
I was the first primary care physician in California to treat liver fibrosis with the first approved medication, Rezdiffra, in 2024.
Significant difficulties referring patients to Stanford, the only source of Fibroscan testing in our area, resulting in risks to my patients, forced me to start in-office Fibroscan testing.
I am one of the first primary care in the Bay Area to offer in-office Fibroscan testing. (Gastroenterolotists commonly do not purchase Fibroscan machines.)
I met in my office with Dr. Naim Alkhouri a world authority who has published 160 papers on liver fibrosis, to discuss my questions about details in several fibrosis publications, gaining further insights into interpreting Fibroscan results and treating fibrosis.<br>